| Literature DB >> 21489261 |
Jan T Kielstein1, Soeren Tolk, Carsten Hafer, Anna Heiden, Olaf Wiesner, Christian Kühn, Johannes Hadem, Marius M Hoeper, Stefan Fischer.
Abstract
BACKGROUND: Extracorporeal lung assist devices are increasingly used in the intensive care unit setting to improve extracorporeal gas exchange mainly in patients with acute respiratory distress syndrome. ARDS is frequently accompanied by acute kidney injury; however it is so far unknown how the combination of these two conditions affects long term survival of critically ill patients.Entities:
Mesh:
Year: 2011 PMID: 21489261 PMCID: PMC3096900 DOI: 10.1186/1471-2369-12-15
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Patient characteristics before iLA insertion (unless otherwise stated).
| all | iLA and ED | iLA - no ED | p | |
|---|---|---|---|---|
| patients | 61 | 21 | 40 | |
| male/female | 30 | 31 | 9 | 12 | 21 | 19 | |
| age (years) | 40 (28 to 52) | 36 (28 to 52) | 41 (28 to 49) | 0.942 |
| iLA treatment (days) | 6 (3 to 11) | 5 (2 to 9) | 7 (5 to 13) | 0.191 |
| iLA-flow after 2 h (l/min) | 1.1 (1.0 to 1.4) | 1.4 (1.3 to 1.6) | 1.1 (1.0 to 1.1) | |
| days on ICU until iLA | 7 (3 to 15) | 8 (5 to 16) | 7 (3 to 12) | 0.880 |
| paO2 (mmHg) | 82 (70 to 98) | 77 (70 to 96) | 82 (70 to 100) | 0.97 |
| after 24 h iLA | 68 (65 to 84) | 71 (62 to 90) | 78 (68 to 83) | 0.900 |
| paCO2 (mmHg) | 100 (81 to 115) | 98 (81 to 114) | 100 (79 to 115) | 0.880 |
| after 24 h iLA | 52 (43 to 61) | 44 (53 to 59) | 56 (45 to 61) | 0.840 |
| pH | 7.15 (7.08 to 7.26) | 7.10 (7.04 to 7.15) | 7.23 (7.13 to 7.27) | |
| after 24 h iLA | 7.38 (7.31 to 7.46) | 7.34 (7.26 to 7.35) | 7.41 (7.33 to 7.46) | |
| Horowitz index (PaO2/FiO2) | 96 (75 to 137) | 98 (77 to 114) | 94 (67 to 144) | 0.280 |
| MAP (mmHg) | 80 (75 to 86) | 80 (70 to 85) | 80 (78 to 87) | 0.249 |
| Pmax (cmH2O) | 38 (34 to 41) | 38 (35 to 40) | 39 (32 to 42) | 0.747 |
| PEEP (cmH2O) | 8 (5 to 10) | 9 (5 to 13) | 8 (5 to 10) | 0.370 |
| Creatinine* (μmol/l) | 53 (40 to 91) | 93 (49 to 174) | 50 (37 to 73) | |
| after 24 h iLA | 52 (34 to 78) | |||
| eGFR* (ml/min/1,73 m2) | 120 (79 to 138) | 66 (33 to 138) | 124 (100 to 140) | |
| SOFA-Score | 11 (10 to 12) | 14 (11 to 17) | 11 (10 to 11) | |
| APACHE II - Score | 32 (28 to 34) | 32 (31 to 38) | 31 (28 to 33) | |
| Vancomycin use day 1-3 of iLA | 32% | 40% | 29% | |
| Aminoglycoside use day 1-3 of iLA | 26% | 13% | 32% | |
| 28 day survival | 33% | 19% | 40% | |
| one year survival | 18% | 5% | 25% | |
Data presented as median (interquartile ranges). *Creatinine and eGFR only from patients without ED dependence before iLA insertion.
Underlying disease and survival at 28 days and one year.
| underlying disease | n | 28 day survival | one year survival |
|---|---|---|---|
| cystic fibrosis | 15 | 27% | 27% |
| pneumonia | 10 | 40% | 20% |
| status post lung Tx | 8 | 25% | 13% |
| pulmonary fibrosis | 7 | 43% | 0% |
| COPD | 7 | 29% | 0% |
| lung cancer | 2 | 50% | 0% |
| pulmonary hypertension | 2 | 100% | 50% |
| leukemia | 2 | 50% | 50% |
| polytrauma | 2 | 50% | 50% |
| others | 6 | 17% | 17% |
Figure 1Depicts the percentage of RRT (renal replacement therapy) dependent patients in relation to the iLA-implantation. Refers to RRT dependent patients (n = 21) only.
Figure 2Kaplan Meier survival curve of patients undergoing iLA treatment only (n = 40) or the combination of iLA treatment and ED (extended dialysis) (n = 21).
Figure 3Kaplan-Meier survival curves of patients successfully bridged to lung transplantation (n = 18) or patients with HU (high urgency) status not being transplanted (n = 17). Survival in both groups was not affected by the need for ED (extended dialysis).